Padcev (enfortumab vedotin-ejfv)

P1/2, N=55, Recruiting, Merck Sharp & Dohme LLC

P2, N=39, Recruiting, Peking Union Medical College | Trial primary completion date: Jul 2026 --> Jul 2028

The patient was referred for systemic therapy with immune checkpoint inhibitors and Enfortumab Vedotin...EUS-guided biopsy with immunohistochemistry is essential to distinguish secondary lesions from primary pancreatic tumors. Accurate diagnosis is crucial to guide systemic therapy, particularly with emerging immunotherapy and antibody-drug conjugates.

One potential target for the ADC Enfortumab Vedotin (EV) is Nectin-4...Nectin-4 could be a potential target in the therapy of women with VSCC. Further (pre-)clinical data is needed to evaluate the use of EV in therapy of women with VSCC.

P1/2, N=348, Terminated, Astellas Pharma Global Development, Inc. | Trial completion date: Sep 2026 --> Feb 2026 | Active, not recruiting --> Terminated; Sponsor stopped the study after meeting enrollment targets and primary objectives, and after collecting sufficient data for planned regulatory filings. The decision was not due to safety concerns, futility, or any regulatory request.

P2, N=60, Active, not recruiting, Fox Chase Cancer Center | Recruiting --> Active, not recruiting

P1, N=37, Not yet recruiting, Generate Biomedicines

P1/2, N=49, Completed, Merck Sharp & Dohme LLC | N=37 --> 49

Over the past decade, multiple ICIs have demonstrated meaningful clinical activity, and their indications have expanded across treatment lines, including second-line therapy after platinum, first-line therapy for cisplatin-ineligible disease, avelumab maintenance following chemotherapy, and, more recently, combination strategies such as pembrolizumab plus enfortumab vedotin. In this review, we provide a comprehensive overview of currently established and emerging biomarkers of ICI response in UBC, including PD-L1 immunohistochemistry, serum inflammatory markers, tumor mutational burden, histology and molecular subtypes, gene expression patterns and microbiome features. We discuss their strengths, limitations, and potential translational relevance, highlighting ongoing challenges and future directions.

P2, N=240, Not yet recruiting, Astellas Pharma Global Development, Inc.

The Food and Drug Administration (FDA)-approved Nectin-4-targeted drug, enfortumab vedotin, has demonstrated substantial efficacy in the treatment of UC...In treatment experiments, covalent 177Lu-FZ-NRs strongly inhibited tumor growth without obvious toxicity. In summary, our novel Nectin-4-targeted covalent bicyclic peptide radioligands provide new molecular imaging tools for the non-invasive assessment of Nectin-4 and establish a foundation for UC-targeted radiotherapy.

Recent advances highlight a rapid surge in positive immunotherapy trials across different head and neck cancer entities, with clinical benefit observed both when immune checkpoint inhibitors are moved earlier in the disease course and when they are combined with agents targeting resistance mechanisms or enabling more precise drug delivery to tumors.